Benlysta
Understanding Benlysta®
Benlysta® (belimumab) is a biologic medication used to treat systemic lupus erythematosus (SLE) and lupus nephritis—autoimmune diseases in which the immune system mistakenly attacks healthy tissues, leading to inflammation and organ damage.
How Benlysta® Works:
- Reduces disease activity and helps manage lupus symptoms.
- Prevents lupus flares by decreasing overactive B cells.
- Protects organs, including the kidneys, in lupus nephritis.
FDA Approvals:
- 2011 – Approved for Systemic Lupus Erythematosus (SLE)
- 2020 – Approved for Lupus Nephritis
For more information, please visit the Benlysta® patient website and speak with your healthcare provider to determine if Benlysta® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: GlaxoSmithKline (GSK) |
CLASS: Monoclonal Antibody (BLyS Inhibitor) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion or Subcutaneous Injection |
|
FREQUENCY: Every two weeks for three doses, then every four weeks. |
Length of infusion: About 60 mins |
FOR MORE INFORMATION: |
Related drugs
